Australian Telehealth Is About to Split in Two. Here's the Side We're Building On.
The Quiet Regulatory Shift That Will Decide Which Telehealth Brands Survive.
Why We're Building Telehealth Brands the Slow Way.
Telehealth won Australia faster than almost anyone predicted. Since 2020, Australians have accessed telehealth consultations more than 86 million times, and the federal government has paid out over $4.4 billion in Medicare benefits for virtual care. The market isn't a pandemic artefact that quietly reverted once clinics reopened — it's structural. Analysts put the local telehealth market at roughly $1.75 billion in 2025, growing at a compound rate above 16% a year through the next decade. Digital health more broadly is on a similar trajectory, driven by an ageing population — more than one in five Australians will be over 65 within the next few years — and rising rates of chronic disease that reward continuous, remote care over episodic GP visits.
That's the growth story every telehealth company puts in its pitch deck. It's true, and it's also not the interesting part.
The interesting part is what happens next. In February 2026, the Therapeutic Goods Administration tightened its guidance on AI-enabled health software, making clear that tools used for diagnosis, monitoring or treatment need to be on the Australian Register of Therapeutic Goods before they can be supplied. It's one line in a broader pattern: regulators catching up to a category that grew faster than its guardrails. More scrutiny of prescribing pathways, advertising claims and clinical governance is coming through 2026 and into 2027, and it will not fall evenly. It will fall hardest on the telehealth operators who scaled on marketing spend and thin clinical oversight — the "wellness" brands that found a workaround to prescription access and built a funnel around it before anyone asked how the medicine was actually being prescribed.
That's the split. On one side: consumer health brands built for conversion first, compliance second — fast to launch, fast to attract regulatory attention, fast to disappear when the rules catch up. On the other: brands built with the clinical and regulatory infrastructure as the foundation, not the afterthought — slower to launch, harder to copy, and still standing when the category matures.
We're building on the second side, deliberately.
Why a portfolio, not a single brand
Precision Bio isn't one telehealth clinic. It's the clinical and compliance infrastructure underneath a portfolio of consumer health brands, each one built to own a distinct category — think metabolic health, hormone-related care, men's and women's health, personalised and preventative medicine — rather than one brand trying to be everything to everyone.
The reasoning is simple: patients don't trust a generalist wellness brand with a specific, often sensitive health need. They trust a brand that looks and speaks like it was built for exactly their situation. But building that kind of trust brand-by-brand, from scratch, on top of a fragmented compliance and clinical stack every time, is slow and expensive — and it's exactly where corners get cut. So we built the infrastructure once: TGA-regulated processes, clinical governance frameworks, AHPRA-aligned prescribing protocols, evidence-based treatment pathways — and we're putting independent, category-specific brands on top of it. Each brand carries the patient relationship. The infrastructure carries the regulatory responsibility. Neither has to compromise to support the other.
What "clinical-first" actually means in practice
It's easy for any healthcare company to claim it's evidence-based. The test isn't the claim, it's what gets built when evidence and speed disagree. For us, that means protocols are designed by the clinicians who'll be accountable for them, not by a growth team working backwards from a conversion funnel. It means every brand under the portfolio operates under full TGA compliance, with no grey-area workarounds on prescribing or advertising. And it means we're recruiting AHPRA-registered doctors and nurse practitioners to help build these protocols from the inside, not to execute someone else's script.
What comes next
We're in build mode. The first consumer brands under the Precision Bio portfolio launch later this year, each one grounded in the infrastructure described above rather than assembled around it after the fact. We're also actively growing our clinical network — if you're an AHPRA-registered doctor or nurse practitioner interested in practising at the top of your license inside a compliance-first telehealth model, we'd like to talk.
Australian healthcare is changing quickly. The next few years will separate the telehealth brands built to last from the ones built to launch. We know which side we're building on — and we'll be sharing more as the first brands come to market.
Follow Precision Bio for updates as our portfolio brands launch, and reach out at connect@precisionbio.au if you're a clinician, investor or potential partner.
